Canurta Journal

Canurta’s CEO presented key research abstracts on glioblastoma and hemp-derived APIs at Canna Pharma 2022 in San Diego. The company also joined the CELS Valley Ready Program, building its presence in the Silicon Valley life sciences ecosystem.

Canurta presented novel glioblastoma research at the Polyphenols Applications World Congress, announced upcoming Canna Pharma participation, and shared its acceptance into both the adMare Executive Institute and AC: Studio programs, further expanding its national leadership in biotechnology.

Canurta presented its glioblastoma research at the Polyphenols Applications World Congress and connected with key partners at the Canadian Health Food Association Tradeshow. The company also celebrated the achievements of its summer research students.

Canurta will present groundbreaking research on cannabis-derived flavonoids for glioblastoma at the 15th Polyphenols Applications World Congress. The company also prepares to showcase its Activated Hemp Seed Powder at Canada’s leading natural health tradeshow.

Canurta highlights progress in biosynthetic research, strategic R&D partnerships, and production scale-up efforts following its presentation at the Canada SynBio Conference.

Canurta is pleased to announce the addition of University of Guelph researchers Dr. Kelly Boddington, Ph.D. and Dr. Eric Soubeyrand, Ph.D. to the team to scale up Canurta’s ability to biosynthetically produce rare hemp polyphenols.

Canurta is pleased to announce that Ethan Russo, MD, the preeminent global medical Cannabis expert, has joined the executive team as Senior Medical Advisor and will provide an exclusive license to related IP through his company CReDO Science, LLC. 

Given the scarcity of Canurta’s novel molecules, they have never been formally assayed in animal or human models. Canurta has committed...